Keywords
How to Cite
Abstract
Material and methods. A total of 125 patients(pts) with HCC (stage BCLC-B) underwent TACE from 2009 to 2016. If pts had been found inoperable, radiological intervention was used as monotherapy or in combination with systemic therapy at different stages of the disease.
Results. Median overall survival (OS) for pts subjected to at least one TACE session was 20.5 months (95 per cent confidence interval 16.4-24.59). Such factors as ECOG status (р=0,012, RR= 1,65), protein synthesis (albumin >37 г/л; р=0,005, RR = 0,47) and detoxication (total bilirubin ≤ 14 мкмоль/л; р=0,037, RR = 1,64) hepatic functions, functional hepatic ability according to Child-Pugh classification (А vs. B; p=0,016, RR = 2,5) ALBI categories (A1 vs. A2 vs. A3; р=0,007, RR = 1,66) as well as HCC invasion: tumour size (р=0,001, RR=2,1), level AFP ≥ 5 IU/ml (р=0,003, RR 2,25), bilobar involvement (р=0,024; RR=1,64) independently influence OS. Pronounced TACE effect (р<0,001, RR 1,93) and Time before Progression duration were found to influence significantly the fatality rate. Multifactorial analysis for OS confirmed increased mortality (RR=1,92) if total bilirubin was ≥14 umol/L (р=0,018); Impaired hepatic functions according to ALBI (р=0,007) and Child-Pugh classification (р=0,002) are associated with significant OS reduction (RR 1.73 и 3,41respectively). HCC invasion (BCLC; р=0,03) AFP level ≥5 IU/ml (р=0,008, RR=2,26) and the biggest tumour node size >10 см (р=0,01, RR 1,95) independently increase mortality rate. Effective TACE (р<0,001) is associated with significant OS increase and mortality decrease.
Conclusion. TACE is most effective if HCC pts have satisfactory condition and preserved liver function (Child Pugh A or ALBIA1) and limited intrahepatic invasion (BCLCA/B), with tumour size being... cm and normal AFP level. Under conditions of intrahepatic progression subsequent local therapy was found to be significantly associated with OS increase.
References
Бредер В.В. Стратегия и тактика консервативного лечения гепатоцеллюлярного рака: дисс.... док-ра мед.наук НМИЦ онкологии им. Н.Н. Блохина. - Москва, 2017. - 309 с
Arimura E. et al. Local recurrence is an important prognostic factor of hepatocellular carcinoma // World J. Gastroenterol. - 2005. - Т 11. - № 36. - С. 5601-5606
Burrel M. et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using DrugEluting Beads. Implications for clinical practice an dtrialdesign // Journal of hepatology. - 2012. - Т. 56. - № 6. - С. 1330-1335
Ferlay J. et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 // Int. J. Cancer. - 2015. - Т. 136. - № 5. - С. E359-E386.
Hsu K.F. et al. Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function // Eur. J. Radiol. - 2012. - Т. 81. - № 3. - С. 466-471.
Imamura H. et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy // J. Hepatol. - 2017. - Т. 38. - № 2. - С. 200-207.
Jeong S.O. et al. Predictive Factors for Complete Response and Recurrence after Transarterial Chemoembolization in Hepatocellular Carcinoma // Gut Liver. - 2017. - Т. 11. - № 3. - С. 1-9.
Johnson P.J. et al. A nssessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach - The albi grade // J. Clin. Oncol. - 2015. - Т. 33. - № 6. - С. 550-558.
Kadalayil L. et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer // Ann. Oncol. - 2013. - Т. 24. - № 10. - С. 2565-2570.
Kohles N. et al. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy // Tumor Biol. - 2012. - Т. 33. - № 1. - С. 33-40.
Llovet J.J.M. et al. Sorafenib in advanced hepatocellular carcinoma // N. Engl. J. Med. - 2008. - Т. 359. - № 4. - С. 378-390.
Llovet J.M. et al. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma // J. Hepatol. - 2012. - Т. 56. - № 4. - С. 908-943.
Nouso K. et al. Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis // Br. J. Cancer. - 2008. - Т. 98. - № 7. - С. 1161 -1165
Takayasu K. et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients // Gastroenterology. - 2006. - Т. 131. - № 2. - С. 461-469
Tateishi R. et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers // Hepatology. - 2006. - Т. 44. - № 6. - С. 1518-1527
Ueno S. et al. Prognosis of hepatocellular carcinoma associated with Child class B and C cirrhosis in relation to treatment: a multivariate analysis of 411 patients at a single center // J. Hepatobiliary. Pancreat. Surg. - 2002. - Т. 9. - № 4. - С. 469-477
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2018